Yichang tianren pharmaceutical co. LTD Company Profile

    Yichang Tianren Pharmaceutical Co., Ltd. was established in 2004 and is a subsidiary of Yichang Renfu Holdings. The company is a high-tech enterprise engaged in the production and sale of chemical raw materials and pharmaceutical intermediates. The company's R&D team consists of multiple engineers, senior engineers, and licensed pharmacists, and has good product development and transformation capabilities. The company currently has 4 GMP certified chemical raw material production lines, with an annual design production capacity of 120 tons of solid chemical raw materials and 30 tons of liquid chemical raw materials.
    The company has more than 20 types of anti-virus, local anesthesia and other products. The company has carried out in-depth cooperation with many well-known domestic pharmaceutical companies. The company's products have been sold to Japan, South Korea, Russia, Italy, Brazil, Egypt and many other countries.
    The company insists on "make conscience medicine and rest assured medicine", pay attention to product quality, strictly produce in accordance with national GMP standards, strictly control quality, and product quality is recognized by customers. While strictly controlling quality, the company does not forget the two corporate social responsibilities of safety and environmental protection. In terms of safety management, in addition to the provision of labor protection supplies and safety facilities, the company has also strengthened employee safety training, and achieved that all employees in key positions have obtained relevant safety operation qualification certificates. Through the company's efforts in safety management, the company passed the three-level safety production standardization certification. In terms of environmental protection management, the construction of the new plant strictly implements the "three simultaneous" environmental protection system. From the beginning of design and construction, the discharge of pollutants has been controlled from the process, and the discharge of sewage has reached the standard.
    The company's next development strategy is to create two series of API products, including antiviral drugs and local anesthetics, and form a production platform for pharmaceutical intermediates. Among them, the antiviral drug valacyclovir hydrochloride has become the leading product, and the new antiviral product Abidor hydrochloride is expected to become a new growth point. The local anesthetics levobupivacaine hydrochloride, ropivacaine hydrochloride, dyclonine hydrochloride, etc. have been submitted to the State Food and Drug Administration for review and are expected to obtain production licenses in this and next two years, and formally enter the market. The pharmaceutical intermediate production platform of the supporting group company has been set up, and many pharmaceutical intermediate production tasks have been completed.